SAN DIEGO, Feb. 14, 2020 /PRNewswire/ -- Biocept,
Inc. (Nasdaq: BIOC), a leading commercial provider of liquid
biopsy tests designed to provide physicians with clinically
actionable information to improve the outcomes of patients
diagnosed with cancer, announces the promotion of Cory J. Dunn, M.S., M. Ed. to Senior Vice
President of Commercial Operations. Ms. Dunn succeeds
Edwin Hendrick, who resigned to
pursue other endeavors.
Ms. Dunn has served as Biocept's Vice President of Commercial
Operations since October 2018. Prior to joining Biocept, she
held multiple leadership positions at life sciences companies
specializing in diagnostics, including GenomeDx Biosciences
(presently Decipher Biosciences), PLUS Diagnostics (presently
Inform Diagnostics) and Genoptix. She holds an M.A. in
education from Stanford University, and
M.S. in Biology and B.S. in Biochemistry and Cell Biology from the
University of California, San
Diego.
"Cory has done a fantastic job over the past several years in
expanding our Target Selector™ strategy into urology and oncology,
and we are delighted that she will head our commercial operations,"
said Michael Nall, Biocept's
President and CEO. "The entire team is united behind Cory's
sales and marketing leadership and we look forward to providing
updates on our commercial progress. I want to thank
Edwin Hendrick for his leadership
and dedication to Biocept and we wish him all the best in his
future endeavors."
"I look forward to taking on this new challenge and am
enthusiastic about working with the commercial team to expand
Biocept's reach and the universe of patients who can benefit from
our Target Selector™ testing," said Ms. Dunn.
About Biocept
Biocept, Inc. is a molecular diagnostics company with
commercialized assays for lung, breast, gastric, colorectal and
prostate cancers, and melanoma. The Company uses its
proprietary liquid biopsy technology to provide physicians with
information for treating and monitoring patients diagnosed with
cancer. The Company's patented Target Selector™ liquid biopsy
technology platform captures and analyzes tumor-associated
molecular markers in both circulating tumor cells (CTCs) and in
plasma (ctDNA). With thousands of tests performed, the
platform has demonstrated the ability to identify cancer mutations
and alterations to inform physicians about a patient's disease and
therapeutic options. For additional information, please
visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this release are not strictly historical, including
without limitation statements as to the expansion in the number of
patients that will have an opportunity to benefit from our liquid
biopsy testing platforms, our ability to improve the outcomes
of patients diagnosed with cancer, and the potential clinical
utility of our proprietary technology platform, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The reader is cautioned not to put undue reliance on these
forward-looking statements, as these statements are subject to
numerous risk factors as set forth in our Securities and Exchange
Commission (SEC) filings. The effects of such risks and
uncertainties could cause actual results to differ materially from
the forward-looking statements contained in this release. We do not
plan to update any such forward-looking statements and expressly
disclaim any duty to update the information contained in this press
release except as required by law. Readers are advised to review
our filings with the SEC, which can be accessed over the Internet
at the SEC's website located at www.sec.gov.
Investors:
LHA Investor
Relations
Jody Cain
Jcain@lhai.com
310-691-7100
Media:
CORE IR
Jules
Abraham
julesa@coreir.com
917-885-7378
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biocept-appoints-cory-j-dunn-senior-vice-president-of-commercial-operations-301004449.html
SOURCE Biocept, Inc.